Novo Nordisk, maker of Ozempic and Wegovy, lowered its 2025 sales outlook for the fourth time, citing slower growth in diabetes and obesity treatments. The company announced 9,000 job cuts and is in a bidding war with Pfizer for Metsera, raising its offer to $10 billion.